2024-02-02 08:00:00 ET
Summary
- Superb quality often comes with a price, which is a lesson that I learned with Stryker.
- The medtech giant's net sales and adjusted diluted EPS both climbed at double-digit clips in Q4.
- Stryker earns a BBB+ credit rating from S&P on a stable outlook.
- Shares have blown past my updated fair value just below $300.
- If a modest pullback were to happen, I would consider initiating a position in Stryker.
As an investor, I'm evolving quite a bit after six years of investing with real money. When I first began, I had this slant toward value over growth that was ingrained in me. This pull to value and high yield admittedly cost me capital appreciation on many occasions....
Read the full article on Seeking Alpha
For further details see:
Stryker: A Dividend Growth Powerhouse I'd Like To Own